The Bridging Antiplatelet Therapy With Cangrelor 2 Study

Recruiting now · Phase 4

Conditions studied: Coronary Arterial Disease (CAD)

In brief

The primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging.

Key facts

Study ID

NCT07225842

Run by

University of Florida

People needed

50

Starts

2026-02-18

Expected to finish

2027-11-01

Last updated by the study team

2026-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any patient receiving bridging with standard-dose cangrelor infusion rate of 0.75 mcg/Kg/min for at least two hours as part of their standard of care.
• Age ≥18 years
• Provide written informed consent.

You may not qualify if…

• Need for urgent surgery
• Confirmed or suspected pregnancy (in woman of child-bearing potential) or lactating females
• Exposure to any oral P2Y12 inhibitor, oral anticoagulant or glycoprotein IIb/IIIa inhibitor within 48 hours.
• Known allergy, and hypersensitivity, or contraindication to cangrelor, mannitol, sorbitol, or microcrystalline cellulose

Where it is running

• University of Florida Jacksonville — Jacksonville, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.